Introduction
Angiotensin-converting enzyme (ACE) 2, a homolog of ACE, is a carboxypeptidase that degrades angiotensin (Ang) II to Ang(1-7) [
1]. Ang(1-7) has vasodilating, antiproliferative, and antithrombotic properties that antagonize the action of Ang II and play vasoprotective roles [
2‐
4]. Recent studies have demonstrated the therapeutic effects of ACE2 activation by a synthetic molecule [
5] or of
ACE2 gene transfer [
6] in experimental pulmonary hypertension models.
Pulmonary arterial hypertension (PAH), a vasculopathy of unknown etiology, is a serious complication of connective tissue disease (CTD) [
7]. One clinical study found reduced metabolism of ACE synthetic substrate in the pulmonary vascular bed of PAH-CTD patients, but not in primary PAH patients [
8]. Persistent digital ischemia, which manifests as skin ulcers or necrotic lesions, is another intractable vasculopathy of CTD, and is strongly associated with Raynaud's phenomenon. A correlation between Raynaud's phenomenon and elevated systolic pulmonary arterial pressure has been reported in patients with systemic lupus erythematosus (SLE) [
9]. PAH or persistent digital ischemia is less frequent than Raynaud's phenomenon, and these three vascular abnormalities are involved in CTD patients across different disease entities, including SLE, systemic sclerosis (SSc), and mixed connective tissue disease (MCTD).
Our preliminary examination suggested the presence of novel autoantibodies to ACE2 in the sera of two patients: a patient with SLE suffering from severe digital necrosis, and a patient with SSc accompanied by lethal PAH. Furthermore, the sera of the two patients lacked ACE2 activity. These findings prompted us to conduct the present study in order to explore the hypothesis that serum autoantibodies to ACE2 predispose patients with CTD to constrictive vasculopathies; that is, PAH and persistent digital ischemia.
Materials and methods
Study design
As many patients as possible among those with CTD and PAH or persistent digital ischemia (vasculopathy patients) in our hospital at time of the study were enrolled. Sera from these patients were studied in comparison with those from CTD patients without vasculopathy or from healthy subjects. The ethics committee of our hospital approved this study, and written informed consent was obtained from all patients and control subjects.
Serum sampling
Fresh serum was obtained from all of the patients and normal subjects for the present study. Each serum sample was aliquoted to avoid repeated thawing and was stocked at -20°C until assayed.
Diagnosis of connective tissue disease
Forty-two patients with SLE, SSc, or MCTD were studied. SLE was diagnosed according to the classification criteria of the American College of Rheumatology [
10]. Patients with SSc met the classification criteria for the diffuse (n = 3) or limited (n = 6) form of SSc, as described in the literature [
11]. Patients with MCTD met the criteria for MCTD from Kasukawa and colleagues [
12] and the original definition of MCTD by Sharp and colleagues [
13].
Diagnosis of pulmonary arterial hypertension
PAH had been diagnosed in five patients with SSc, based on dyspnea on exertion, elevated plasma brain natriuretic peptide levels >100 pg/ml, right ventricular outflow and peak tricuspid regurgitant pressure gradient exceeding 30 mmHg on echocardiography, exclusion of pulmonary thromboembolism by high-resolution computed tomography or pulmonary scintigraphy, and no deteriorated lung fibrosis that could cause pulmonary hypertension.
Diagnosis of persistent digital ischemia
Each of the 16 patients in this category had persistent cyanotic lesions on the digits, present for more than 2 years at the time of the present study, and a history of or existing digital ulcers or necrosis. The radial artery pulse in each patient was normal, and atherosclerotic ischemia was excluded clinically. Three of the 16 patients also had PAH.
Control patients
Serum samples from 24 CTD patients who had neither PAH nor persistent digital ischemia were collected randomly (that is, independent of the activity of their CTD) on the ward or in the outpatient clinic. These samples served as disease controls.
Normal control subjects
Serum samples were obtained from 28 healthy volunteers (23 females and five males) who were free from any active or chronic diseases, including hypertension. Before bleeding, each subject was confirmed to have normal blood pressure in the arms. The mean age of the 28 subjects was 32.0 ± 9.5 years.
Detection of anti-ACE2 antibodies in patient serum
We established an ELISA using purified recombinant human ACE2. A plasmid DNA-encoding human ACE2 cDNA, which was kindly gifted from Dr Hyeryun Choe (Harvard Medical School, Cambridge, MA, USA), was introduced into 293 free-style cells, according to the manufacturer's protocol (Invitrogen, Carlsbad, CA, USA). Culture supernatant was harvested on day 2 after transfection, dialyzed against 25 mM Tris-Cl (pH 8.5), and applied onto a DEAE column. ACE2 was eluted with 250 mM NaCl, and was dialyzed against for further use. About 12.5 μg/ml recombinant human ACE2 were first coated overnight onto a 96-well plate with bicarbonate buffer (pH 9.6) at 4°C. The wells were then treated with a blocking buffer composed of 5% BSA in PBS and washed with buffer composed of 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 0.1% Tween 20. The sera of the patients and normal healthy volunteers were added to the plate and incubated for 1 hour at room temperature. Bound ACE2 antibodies were detected using horseradish peroxidase-conjugated anti-human IgG antibody. The optical density at 450 nm was measured after a 30-minute incubation with SureBlue TMB microwell peroxidase substrate (Kirkegaard & Perry Laboratories Inc., Gaithersburg, MD, USA). All samples were analyzed in triplicate, and the values were normalized with the positive control.
Measurement of serum ACE2 activity
Zinc-dependent ACE2 enzymatic activity was measured according to the methods described previously [
14,
15]. Briefly, 20 μM (7-methoxycoumarin-4-yl) acetyl-APK-(2,4-dinitrophenyl)-OH (amino acids depicted by single letters) (AnaSpec Inc., Fremont, CA, USA) - a fluorogenic substrate [
14] - was incubated with 1 μl test serum. Fluorescence was monitored using Safire2 (TECAN, Männedorf, Switzerland) at the excitation and emission wavelengths of 320 nm and 450 nm, respectively.
Preliminary experiments revealed that the relative fluorescence unit (RFU) value was not increased when the substrate was simply incubated without the enzyme (data not shown). Among 20 healthy humans, two samples showed significantly high autofluorescence - in these cases, the RFU values decreased during the incubation even with the substrate. We excluded these samples because it was not possible to evaluate the ACE2 enzyme activity.
The RFU values obtained by the APK substrate were almost completely inhibited by an ACE2 inhibitor, DX600 (Phoenix Pharmaceuticals Inc., Burlingame, CA, USA) (Additional file
1). Additionally, the RFU values were statistically significant at both 60 and 70 minutes of the incubation (Additional file
2). Based on these observations, we used the RFU values at 70 minutes without subtracting the residual RFU counts resistant to DX600 [
15]. The relative ACE2 activity (%) in each sample was further calculated based on the level of ACE2 activity in a mixture of serum samples from 28 healthy subjects (a reference serum). The assay was performed in triplicate and the mean values of three independent measurements of the ACE2 ELISA and ACE2 activity assay were used for the statistical analysis by Student's
t test.
Detection of serum ACE2 protein
An anti-human ACE2 goat polyclonal antibody (R&D Systems, Minneapolis, MN, USA) was used for immunoprecipitation. Serum was first treated for 15 minutes with 100 mM MgCl2, 70 units DNase I (Takara Bio Inc., Shiga, Japan) and 500 μg/ml Ribonuclease A (Sigma, St Louis, MO, USA) at room temperature, and was then incubated with anti-human ACE2 antibody at 4°C for 2 hours. After incubation, the immune complexes were recovered using Protein G Sepharose™ 4 Fast Flow (GE Healthcare, Amersham, Buckinghamshire, UK) and subjected to SDS-PAGE, followed by western blot analysis. To detect ACE2 proteins, an anti-human ACE2 mouse monoclonal antibody was used (R&D Systems).
Purification of IgG from serum
Five microliters of serum were incubated with Protein G Sepharose™ 4 Fast Flow in 20 mM sodium phosphate buffer (pH 7.0) for 2 hours at 4°C. The immune complexes were then washed and the IgG-bound beads eluted with 0.1 M glycine-HCl (pH 2.7). The recovered IgG was immediately neutralized with 1 M Tris-HCl (pH 8.0). IgG was detected by SDS-PAGE followed by Coomassie Brilliant Blue staining. IgG fractions were prepared from three vasculopathy patients and three healthy subjects. The effect of each IgG on the activity of recombinant human ACE2 (standard rACE2; R&D Systems) was examined as described.
Discussion
Persistent digital ischemia and clinically evident PAH are intractable and relatively infrequent complications of SLE, SSc, and MCTD - although latent forms of vasculopathies, including sporadic abnormalities such as Raynaud's phenomena, may be more prevalent in CTD patients. Immunosuppressive therapy can improve PAH in some patients with SLE, SSc, or MCTD [
16], and in most SLE patients [
17] via an unknown therapeutic mechanism. The treatment of digital ischemia remains an unsolved clinical problem for physicians. Our study suggests, for the first time, that autoantibodies to ACE2 are present in the serum of patients with persistent constrictive vasculopathies. Furthermore, the elevated ELISA scores for anti-ACE2 antibodies correlated with reduced ACE2 activity. The serum autoantibodies to ACE2 may therefore inhibit ACE2 activity, and the inhibition may be reversible after immunosuppressive therapy, based on the data from Patient 1. There were small numbers of patients with systemic hypertension in both the vasculopathy and control patient groups. We could not determine whether their hypertension was essential hypertension, or was caused by steroid therapy or ACE2 inhibition.
The inhibition of ACE2 by autoantibodies may result in reduced physiological levels of the vasoprotective agent Ang(1-7) in the local vascular milieu, which may induce vasculopathies in patients with underlying disease such as CTD. Vasodilating drugs - including prostanoids, endothelin-receptor antagonists, and phosphodiesterase type-5 inhibitors - have been used widely to treat PAH and have been partially effective for some PAH patients [
18]. No effective drugs have been found for persistent digital ischemia [
19]. Our study suggests that ACE2 activation or administration in experimental PAH [
5,
6] may be applicable as a therapy for PAH or persistent digital ischemia in patients with CTD.
Acknowledgements
The authors thank Dr Hyeryun Choe (Harvard Medical School, Cambridge, MA, USA) for a plasmid DNA encoding human ACE2 cDNA. The present work was supported by Grants-in-Aid for Research on Intractable Diseases from the Ministry of Health, Labor, and Welfare of Japan.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
YT and SH equally contributed to this study. YT performed the ELISA, clinical practice, and wrote the paper. SH prepared a recombinant ACE2 protein, carried out the assays for ACE2 activities, and wrote the methods. YI designed the experiments. AM designed the research and completed the paper.